Press Releases

Date Title and Summary Additional Formats
Toggle Summary NOVELOS THERAPEUTICS DEVELOPING CLR1502 (GLOW2) CANCER-TARGETED OPTICAL IMAGING AGENT FOR INTRAOPERATIVE TUMOR MARGIN ILLUMINATION
NOVELOS THERAPEUTICS DEVELOPING CLR1502 (GLOW2) CANCER-TARGETED OPTICAL IMAGING AGENT FOR INTRAOPERATIVE TUMOR MARGIN ILLUMINATION Expects to File IND in Second Half of 2013 MADISON, Wisc. (August 28, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs
View HTML
Toggle Summary NOVELOS THERAPEUTICS TO PRESENT AT LHA LIFE SCIENCES & MEDICAL TECHNOLOGIES VIRTUAL CONFERENCE ON JUNE 28
NOVELOS THERAPEUTICS TO PRESENT AT LHA LIFE SCIENCES & MEDICAL TECHNOLOGIES VIRTUAL CONFERENCE ON JUNE 28 MADISON, WI, June 27, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry S.
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES POSITIVE INITIAL IMAGING RESULTS IN BRAIN CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER
NOVELOS THERAPEUTICS ANNOUNCES POSITIVE INITIAL IMAGING RESULTS IN BRAIN CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER Expects Final Imaging Results in the First Quarter 2013 MADISON, WI, June 19, 2012 – Novelos Therapeutics, Inc.
View HTML
Toggle Summary NOVELOS THERAPEUTICS CLOSES $5.4 MILLION PUBLIC OFFERING
NOVELOS THERAPEUTICS CLOSES $5.4 MILLION PUBLIC OFFERING Announces Dismissal with Prejudice of Putative Federal Securities Class Action Lawsuit MADISON, WI, June 14, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of
View HTML
Toggle Summary NOVELOS THERAPEUTICS PRICES $5.4 MILLION PUBLIC OFFERING
NOVELOS THERAPEUTICS PRICES $5.4 MILLION PUBLIC OFFERING NOVELOS THERAPEUTICS PRICES $5.4 MILLION PUBLIC OFFERING MADISON, WI, June 8, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the
View HTML
Toggle Summary NOVELOS THERAPEUTICS SUCCESSFULLY COMPLETES FIRST COHORT IN PHASE 1b SOLID TUMOR TRIAL WITH I-131-CLR1404 (HOT) CANCER-TARGETED MOLECULAR RADIOTHERAPEUTIC
NOVELOS THERAPEUTICS SUCCESSFULLY COMPLETES FIRST COHORT IN PHASE 1b SOLID TUMOR TRIAL WITH I-131-CLR1404 (HOT) CANCER-TARGETED MOLECULAR RADIOTHERAPEUTIC First Patient Enrolled in Second Cohort, Additional Clinical Results Expected in Q3 2012 Expects to Begin Phase 2 Proof-of-Concept Trials in Q1
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF FIRST COHORT IN LUNG CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER
NOVELOS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF FIRST COHORT IN LUNG CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER Demonstrates Positive Initial Imaging Results; Additional Clinical Results Expected by mid-2012 MADISON, WI, April 24,
View HTML
Toggle Summary NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS PRESENT THREE POSTERS AT 2012 AACR ANNUAL MEETING
NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS PRESENT THREE POSTERS AT 2012 AACR ANNUAL MEETING Broad-Spectrum, Cancer-Targeting Therapeutic and Diagnostic Agents Described MADISON, WI, April 3, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN BRAIN CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER
NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN BRAIN CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER Expects Initial Imaging Results in the Second Quarter of 2012 MADISON, WI, March 15, 2012 – Novelos Therapeutics, Inc.
View HTML
Toggle Summary NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS HAVE THREE ABSTRACTS ACCEPTED FOR PRESENTATION AT 2012 AACR ANNUAL MEETING
NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS HAVE THREE ABSTRACTS ACCEPTED FOR PRESENTATION AT 2012 AACR ANNUAL MEETING Broad-Spectrum, Cancer-Targeting Therapeutic and Diagnostic Agents Described MADISON, WI, March 1, 2012 – Novelos Therapeutics, Inc.
View HTML